LA
RCKT icon

Lee Ainslie’s Rocket Pharmaceuticals RCKT Stock Holding History

Lee Ainslie’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
3,923,963
+356,591
+10% +$1.19M 0.12% 48
2026
Q1 		$12.8M Buy
3,567,372
+1,054,262
+42% +$4.19M 0.15% 52
2025
Q4 		$8.82M Sell
2,513,110
-5,955,234
-70% -$20.4M 0.09% 56
2025
Q3 		$27.6M Buy
8,468,344
+104,531
+1% +$329K 0.37% 50
2025
Q2 		$20.5M Buy
8,363,813
+3,164,595
+61% +$16M 0.31% 49
2025
Q1 		$34.7M Buy
5,199,218
+318
+0% +$3.14K 0.61% 46
2024
Q4 		$65.4M Buy
5,198,900
+1,080,228
+26% +$16.3M 1.18% 30
2024
Q3 		$76.1M Buy
4,118,672
+190,360
+5% +$3.9M 1.48% 23
2024
Q2 		$84.6M Buy
3,928,312
+40,000
+1% +$919K 1.6% 21
2024
Q1 		$105M Sell
3,888,312
-145,756
-4% -$4.14M 1.97% 13
2023
Q4 		$121M Sell
4,034,068
-1,595,902
-28% -$35.2M 2.43% 6
2023
Q3 		$115M Buy
5,629,970
+1,250,000
+29% +$22.7M 2.61% 7
2023
Q2 		$87M Sell
4,379,970
-27,653
-0.6% -$559K 1.86% 15
2023
Q1 		$75.5M Buy
4,407,623
+1,011,805
+30% +$19.8M 1.91% 11
2022
Q4 		$66.5M Buy
3,395,818
+863,452
+34% +$15.9M 1.57% 16
2022
Q3 		$40.4M Hold
2,532,366
– – 0.91% 23
2022
Q2 		$34.8M Buy
2,532,366
+399,200
+19% +$4.76M 0.86% 24
2022
Q1 		$33.8M Buy
2,133,166
+238,200
+13% +$4.12M 0.59% 37
2021
Q4 		$41.4M Buy
1,894,966
+234,850
+14% +$6.41M 0.47% 47
2021
Q3 		$49.6M Buy
1,660,116
+1,486,229
+855% +$54.1M 0.5% 44
2021
Q2 		$7.7M Buy
+173,887
New +$7.55M 0.07% 85

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Lee Ainslie's RCKT Position: Q2 2026 in Review

Lee Ainslie increased its Rocket Pharmaceuticals (RCKT) stake by 10% in Q2 2026, buying an estimated $1.19M and bringing the position to 3,923,963 shares worth $13.4M. The position accounts for 0.12% of the portfolio, ranked #48.

Lee Ainslie first reported a position in RCKT in Q2 2021 and has held it in 21 quarters since. The position peaked at $121M in Q4 2023. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Lee Ainslie held 3,923,963 shares of Rocket Pharmaceuticals worth $13.4M as of Q2 2026.
  • Lee Ainslie bought 356,591 Rocket Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
  • Rocket Pharmaceuticals made up 0.12% of Lee Ainslie's portfolio in Q2 2026, its #48 holding.
  • Lee Ainslie first reported a position in Rocket Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Lee Ainslie's Rocket Pharmaceuticals position peaked at $121M in Q4 2023.
  • 178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Maverick Capital's 13F filing for Q2 2026, filed 14 Aug 2026.